

# Diabetes, Obesity and Covid-19 Infection

Azwin Baskoro\*

Azwin Baskoro. Diabetes, Obesity and Covid-19 Infection. *J Food Clin Nut* 2021;4(4):1-2.

The expanded occurrence of weight, diabetes, and cardiovascular risk factors in people hospitalized with extreme COVID-19 infection has incited impressive interest within the metabolic parts of SARS-CoV-2-initiated pathophysiology. The metabolic issues and their co-morbidities modify the

susceptibility to, normal history, and likely treatment of SARS-CoV-2 disease, with an emphasis on human science. New information educating hereditary inclination, the study of disease transmission, invulnerable reactions, infection seriousness, and treatment of COVID-19 in people with obesity and diabetes are featured.

**Keywords:** Diabetes; obesity; Covid 19

### DESCRIPTION

The world is completely occupied with all parts of the COVID-19 pandemic, which has upset the wellbeing and prosperity of people and nations on a worldwide scale. The hitting powerlessness of people with cardiovascular infection (CVD), type 2 diabetes (T2D), and obesity to extreme instances of COVID-19, apparent by expanded paces of hospitalization and mortality, has concentrated of the endocrine and digestion local area on the pandemic, both in the research center and in the clinic. The improved pervasiveness of diabetes and obesity and more outstanding paces of negative results in hospitalized subjects with COVID-19 bring up significant logical issues with quick clinical indications. These range from the degree, assuming any, of unbalanced dysregulation; the general significance of systems inclining to upgraded disease intensity; term of viral shedding; the reaction to immunizations; the significance of advancing metabolic control; and the wellbeing, and possible advantages of regularly utilized medications, in individuals with T2D and obesity. Additionally, a most of the reports has raised different contending speculations encompassing the pathophysiology of SARS-CoV-2 contamination in individuals with diabetes and weight, incorporating the gastrointestinal tract, liver, islets, and fat tissue. People with COVID-19 and T1D do not invariably exhibit an increased risk for hospitalization or more severe illness; however, older subjects with T1D exhibit higher rates of COVID-19-related mortality, as described in the Coronavirus-SARS-CoV-2 and Diabetes Outcomes. After changing age, gender, and geographic area, the adjusted odds ratio of hospital mortality for COVID-19 is 3.51 and 2.03 for T1D and T2D, respectively. However, COVID-19 infection has led to an increase in the hospitalization rate and severity of infections in patients with type 1 diabetes, type 2 diabetes, or obesity. T2D and obesity are metabolic issues characterised by improper functioning of immune system, with increased accumulation of immune cells in different tissues, which thus empowers an uplifted condition of basal irritation by means of upgraded cytokine and chemokine creation, prompting disability of  $\beta$  cell capacity and intensification of insulin opposition. These insusceptible cell populaces incorporate macrophages, neutrophils, eosinophils, T cells, B cells, and dendritic cells, altogether disabling the control of insulin activity and energy homeostasis. All in all, these gained anomalies extensively hinder cell safe capacity, likely adding to upgraded initiation of the NLRP3 inflammasome, and a more noteworthy powerlessness to contamination in weak people.

Hyperglycemia can improve the replication of SARSCoV2 in monocytes, expand the superficial connection of ACE2, and increase the favorable

response of monocytes to cytokine stimulation in vitro. Also, monocytes confined from people with T2D or corpulence showed more prominent defenselessness to SARS-CoV-2 disease ex vivo. Additionally, the significance of glucose digestion for monocyte contamination was shown utilizing the glycolysis inhibitor 2-deoxyglucose, which impeded viral replication and constricted enlistment of ACE2 and cytokine articulation, discoveries impersonated by substance hindrance of glycolysis. Many glycolysis-related properties in SARSCoV2 disease and monocytes are attributed to the up-regulation of HIF1 $\alpha$ .

### CONCLUSION

The COVID-19 global pandemic causes significant health hazards, especially for patients with diabetes mellitus. The conclusive treatment or antibodies for COVID-19 presently not yet discovered. Therefore, suppressing infection is the best solution. Under these conditions, patients with diabetes mellitus need to make an attempt to keep healthy lifestyle and to reduce potential risk factors.

### REFERENCES

1. Vas P, Hopkins D, Feher M, Rubino F, B Whyte M. Diabetes, obesity and COVID-19: a complex interplay. *Diabetes, Obesity and Metabolism*. 2020;22:1892-1896.
2. Holder K, Reddy PH. The COVID-19 effect on the immune system and mitochondrial dynamics in diabetes, obesity, and dementia. *The Neuroscientist*. 2021;27:331-339
3. Shah H, Khan MS, Dhurandhar NV, Hegde V. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. *Acta diabetologica*. 2021 15:1-3.
4. Smith SM, Boppana A, Traupman JA, Unson E, Maddock DA, Chao K, Dobesh DP, Brufsky A, Connor RI. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. *Journal of medical virology*. 2021;93:409-415.
5. Kruglikov IL, Shah M, Scherer PE. Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral-bacterial interactions. *Elife*. 2020;9:e61330.

---

Faculty of Medicine, IPB University, Indonesia.

\*Correspondence to: Azwin Baskoro, Faculty of Medicine, IPB University, Indonesia; E-mail: azwin-b@fk.ac.id

---

**Citation:** Baskoro A (2021) Diabetes, Obesity and Covid-19 Infection. *J Food Clin Nut*. 4(4)

**Received date:** August 06, 2021; **Accepted date:** November 09, 2021; **Published date:** November 19, 2021



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [reprints@pulsus.com](mailto:reprints@pulsus.com)